1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells
(
- Contribution to journal › Article
- 2018
-
Mark
WNT5A as a therapeutic target in breast cancer
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
(
- Contribution to journal › Article
-
Mark
Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion
(
- Contribution to journal › Article
- 2016
-
Mark
WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition
(
- Contribution to journal › Article
-
Mark
Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells
(
- Contribution to journal › Article
- 2015
-
Mark
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression.
(
- Contribution to journal › Article
- 2013
-
Mark
WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells
(
- Contribution to journal › Article